Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab
October 20 2021 - 12:00PM
Business Wire
Partnership will focus on developing analytical
solutions to better characterize bioprocesses towards improved
quality, yields and efficiency
News Summary:
- Waters and University of Delaware announce a multi-year
collaboration to develop technology for analytical characterization
of manufacturing processes for biologics and novel modalities.
- Waters’ staff and university researchers will co-locate at
Immerse™ Delaware, an Innovation and Research Lab, a new state of
the art lab located at the Science, Technology and Advanced
Research Campus of University of Delaware, also home to the
National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL).
- Projects will address needs of biopharmaceutical industry to
improve drug product quality, yields, process efficiency and
process control using LC-MS and adjacent analytical
technologies.
Waters Corporation (NYSE:WAT) and the University of Delaware
today announced a five-year research partnership to develop new
analytical solutions for bioprocessing and biomanufacturing. Key to
this partnership is Immerse™ Delaware, an Innovation and Research
Lab, (“Immerse Delaware”) set to open in early 2022 located at the
University of Delaware Science, Technology and Advanced Research
(STAR) campus. At Immerse Delaware, Waters will partner with
students and faculty to identify and address the most significant
challenges facing the biopharmaceutical industry.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211020005746/en/
The success of biotherapeutics such as monoclonal antibodies
(mAbs), cell and gene therapies and vaccines has transformed the
life sciences industry. However, the optimization of the
manufacturing process of these complex medicines has been limited
by the lack of robust analytical methods that clearly decouple the
critical quality attributes of the product from the process
parameters. Waters is partnering with University of Delaware
because of its leadership in chemical and biological manufacturing
research as well its active support and close proximity to the
National Institute for Innovation in Manufacturing
Biopharmaceuticals (NIIMBL), a collaborative effort amongst
industry, academia, and regulators.
“We strongly believe that the most difficult challenges can only
be solved through collaboration across academia and industry.
Immerse Delaware follows from our highly successful launch of
Immerse Cambridge, A Waters Innovation and Research Lab,” said Dr.
Udit Batra, CEO and President of Waters Corporation. “Through this
collaboration, researchers from both Waters and University of
Delaware will identify and develop solutions that can better
characterize biological manufacturing processes and drive
improvements in quality, yields, efficiency and process control.
Our partnership eventually aspires to decouple the product from the
process, which can significantly accelerate the delivery of higher
quality medicines to patients.”
"We are thrilled that an industry-leading innovator like Waters
Corporation and the University of Delaware are forming this
collaborative partnership to advance novel solutions to
biopharmaceutical process development and manufacturing,” said Dr.
Dennis Assanis, President, University of Delaware. “This is a true
testimony to UD’s recognition as a national hub for innovation and
talent development that feeds cutting edge progress across
industries — including engineering, biopharmaceuticals, life
sciences, and so much more. The Waters-UD groundbreaking initiative
will help accelerate development of life-saving medicines, while
simultaneously developing the workforce of the future.”
The Immerse Delaware Lab will feature a purpose-built research
test bed, with a focus on leveraging LC-MS and adjacent
technologies to support bioprocess engineers’ empirical data in the
areas of process and informatics. Initial projects at Immerse
Delaware will seek to gain a deeper understanding of novel schemes
to quantify and ultimately minimize process-related impurities from
uncontrolled glycosylation, which negatively impacts drug efficacy.
These will be paired with informatic solutions to predict the
evolution of biotherapeutic products.
Through its strategy to invest in academic and external
partnerships, Waters is fostering a global community of scientific
collaborators and innovators. Immerse Delaware, and future Immerse
laboratories, will enable Waters to tap into a new set of talent
and drive diversity of thought in its mission to improve human
health and well-being.
In addition to investing in Immerse Delaware, Waters has
furthered its commitment to biopharmaceutical innovation by joining
NIIMBL. Located at the University of Delaware STAR campus, NIIMBL
is a public-private partnership pursuing its mission to accelerate
biopharmaceutical innovation, support the development of standards
that enable more efficient and rapid manufacturing capabilities,
and educate and train a world-leading biopharmaceutical
manufacturing workforce, to fundamentally advance U.S.
competitiveness in this industry.
Additional Resources
- Learn more about Immerse, a Waters Innovation & Research
Lab
- Learn more about the University of Delaware’s STAR Campus
- Connect with Waters via Twitter, Facebook and LinkedIn
About the University of Delaware (www.udel.edu)
The University of Delaware, located in Newark, Delaware, traces
its beginnings to a small private academy established in 1743.
Today, UD is a research-intensive, technologically advanced
institution offering more than 150 academic majors across nine
colleges, serving more than 23,000 undergraduate and graduate
students. The University's distinguished faculty includes
internationally renowned authors, scientists and artists. The
Carnegie Foundation for the Advancement of Teaching has classified
UD as having very high research activity—a designation accorded
fewer than 3% of U.S. colleges and universities. The University’s
Science, Technology and Advanced Research (STAR) Campus in Newark
is a growing center for innovation, blending cutting-edge research,
top-notch academics and thriving businesses in one location.
Delaware has 21 varsity sports teams that compete at the Division 1
level in the Colonial Athletic Association and the Football
Championship Subdivision.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), Waters Corporation (NYSE:WAT),
the world's leading specialty measurement company, has pioneered
chromatography, mass spectrometry, and thermal analysis innovations
serving the life, materials, food and environmental sciences for
more than 60 years. With more than 7,400 employees worldwide,
Waters operates directly in 35 countries, including 14
manufacturing facilities, and with products available in more than
100 countries.
Waters and Immerse are trademarks of Waters Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211020005746/en/
Media Contacts:
Peter Kerwin Manager, Media Relations University of Delaware
pgkerwin@udel.edu
Chris Orlando Corporate Communications Waters Corporation
chris_orlando@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024